Skip to main content
KVUE
NYSE Life Sciences

Kimberly-Clark to Acquire Kenvue for $48.7 Billion, Offering $21.01 Per Share

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
10
Price
$17.01
Mkt Cap
$32.591B
52W Low
$14.02
52W High
$25.17
Market data snapshot near publication time

summarizeSummary

Kimberly-Clark Corporation is set to acquire Kenvue Inc. in a cash and stock transaction valued at approximately $48.7 billion, with Kenvue shareholders receiving $21.01 per share.


check_boxKey Events

  • Acquisition Terms Announced

    Kimberly-Clark Corporation proposes to acquire Kenvue Inc. for an enterprise value of approximately $48.7 billion, with Kenvue shareholders receiving $21.01 per share in cash and stock.

  • Significant Premium Offered

    The $21.01 per share consideration represents a substantial premium over Kenvue's current stock price of $17.01, offering immediate value to shareholders.

  • Strategic Rationale and Synergies

    The merger aims to create a global health and wellness leader, combining complementary consumer offerings and targeting approximately $2.1 billion in total anticipated run-rate synergies.

  • Shareholder Votes Scheduled

    Both Kimberly-Clark and Kenvue will hold special meetings for shareholder approval on January 29, 2026, with the transaction expected to close in the second half of 2026.


auto_awesomeAnalysis

This filing confirms the proposed acquisition of Kenvue by Kimberly-Clark, a transformative event for Kenvue shareholders. The offer of $21.01 per share represents a significant premium over Kenvue's current trading price, indicating a substantial immediate gain for investors. The combined entity aims to create a global health and wellness leader, leveraging complementary portfolios and targeting significant synergies. While regulatory and shareholder approvals are still pending, the unanimous board approvals and scheduled shareholder votes suggest a clear path forward. Investors should monitor the shareholder votes and any potential regulatory hurdles, but the deal fundamentally alters the investment thesis for Kenvue.

At the time of this filing, KVUE was trading at $17.01 on NYSE in the Life Sciences sector, with a market capitalization of approximately $32.6B. The 52-week trading range was $14.02 to $25.17. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed KVUE - Latest Insights

KVUE
Mar 06, 2026, 12:37 PM EST
Source: Reuters
Importance Score:
7
KVUE
Feb 20, 2026, 7:13 AM EST
Filing Type: 10-K
Importance Score:
8
KVUE
Feb 17, 2026, 4:46 PM EST
Filing Type: 8-K
Importance Score:
7
KVUE
Feb 12, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
KVUE
Jan 29, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
7
KVUE
Jan 27, 2026, 5:21 PM EST
Filing Type: 425
Importance Score:
9
KVUE
Jan 16, 2026, 5:29 PM EST
Filing Type: 425
Importance Score:
8
KVUE
Jan 16, 2026, 5:28 PM EST
Filing Type: 425
Importance Score:
8
KVUE
Jan 16, 2026, 5:27 PM EST
Filing Type: 8-K
Importance Score:
7
KVUE
Jan 16, 2026, 5:23 PM EST
Filing Type: 425
Importance Score:
7